Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.

Nicola Fazio; Dan Granberg; Ashley Grossman; Stephen Saletan; Judith Klimovsky; Ashok Panneerselvam; Edward M Wolin

doi:10.1378/chest.12-1108

Publisher Website

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.

Authors

Fazio, Nicola¹
Granberg, Dan²
Grossman, Ashley³
Saletan, Stephen⁴
Klimovsky, Judith⁴
Panneerselvam, Ashok⁴
Wolin, Edward M⁵

¹ European Institute of Oncology, Milan, Italy. Electronic address: [email protected] , (Italy)
² Departments of Medical Sciences and Endocrine Oncology, Uppsala University, Uppsala, Sweden. , (Sweden)
³ Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital University of Oxford, Oxford, England.
⁴ Novartis Pharmaceuticals Corp, Florham Park, NJ.
⁵ Cedars-Sinai Medical Center, Los Angeles, CA.

Type

Published Article

Journal

CHEST Journal

Publisher

Elsevier

Publication Date

April 2013

Volume

143

Issue

4

Pages

955–962

Identifiers

DOI: 10.1378/chest.12-1108

PMID: 23187897

Source

Medline

License

Unknown

Abstract

ClinicalTrials.gov; No.: NCT00412061

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/23187897

Report this publication

Statistics

Seen <100 times